CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI
- PMID: 16546302
- DOI: 10.1016/j.neurobiolaging.2006.02.001
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI
Abstract
Background: The patients with mild cognitive impairment (MCI) have an elevated risk for Alzheimer's disease (AD). Especially the amnestic MCI is seen as prodrome of AD. Apolipoprotein E (APOE) epsilon4 allele, abnormal CSF Abeta42, Tau and phosphorylated Tau (phospho-Tau) levels are associated with elevated risk for AD.
Methods: APOE genotyping was done by PCR based method and baseline CSF Abeta42, Tau and phospho-Tau were measured by ELISA from 60 controls and 79 MCI patients.
Results: Thirty-three MCI patients developed dementia during an average of 3.5 years follow-up. CSF Abeta42 was decreased and Tau and phospho-Tau were increased in the progressive MCI patients. The APOE epsilon4 allele was more frequent in the progressive MCI patients. The APOE epsilon4 allele showed a dose dependent association o the Abeta42 levels in the progressive MCI patients and to all of the markers in controls.
Conclusions: Decreased CSF Abeta42 and elevated Tau or phospho-Tau together with APOE epsilon4 allele are highly predictive for the dementia in MCI patients with amnestic or executive symptoms.
Comment in
-
Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia.Neurobiol Aging. 2007 Oct;28(10):1631-2; discussion 1633-4. doi: 10.1016/j.neurobiolaging.2006.07.019. Epub 2006 Sep 7. Neurobiol Aging. 2007. PMID: 16962213
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous